Product Information
Registration Status: ActiveFASLODEX SOLUTION FOR INJECTION 250mg/5ML is approved to be sold in Singapore with effective from 2006-06-09. It is marketed by ASTRAZENECA SINGAPORE PTE LTD, with the registration number of SIN13216P.
This product contains Fulvestrant 50mg/ml in the form of INJECTION, SOLUTION. It is approved for INTRAMUSCULAR use.
This product is manufactured by Vetter Pharma-Fertigung GmbH in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Mechanism of Action
Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines.
Toxicity
There is no clinical experience with overdosage in humans.
Active Ingredient/Synonyms
ICI 182,780 | Fulvestrant |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.